To include your compound in the COVID-19 Resource Center, submit it here.

Ruxolitinib: Phase III ongoing

Incyte disclosed in its 2Q11 earnings that it and Novartis plan to amend the open-label, international Phase III RESPONSE trial of INCB18424 to accelerate enrollment due to recruitment being

Read the full 292 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE